Streetbeat News

Products Services

INMB

INmune Bio's INKmune has shown excellent safety and increased NK-cell activity in the first dosing cohort of its Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC).

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:17 pm

BTCUSD

Anthony Pompliano predicts Bitcoin will benefit from increased global liquidity due to recent monetary policy changes, including a Federal Reserve interest rate cut. He highlights Bitcoin's sensitivity to liquidity changes and notes that over 50% of Bitcoin is held long-term.

Portfolio Pulse from Murtuza Merchant

September 26, 2024 | 12:17 pm

INZY

Inozyme Pharma presented new data at ASBMR 2024, emphasizing the urgent need for therapies for cardiovascular and musculoskeletal complications in ENPP1 and ABCC6 deficiencies. They also launched the PROPEL Registry to enhance understanding of these rare diseases.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:17 pm

CHPT

ChargePoint (NYSE:CHPT) is focusing on future trends and innovations in the EV charging industry to maintain its leadership. The company is developing products for all market segments and classifications of electric vehicles.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:17 pm

PSTG

RBRK

Rubrik and Pure Storage have announced a partnership to enhance cyber resilience by integrating Rubrik Security Cloud with Pure Storage's platform. This collaboration aims to provide improved data protection and rapid recovery solutions in response to increasing cyber threats.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:16 pm

CRVO

CervoMed Inc. (NASDAQ:CRVO) will present findings on neflamapimod for treating dementia with Lewy bodies at the 17th Clinical Trials on Alzheimer's Disease Conference in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:16 pm

NCNA

NuCana's shares have risen following the announcement of a U.S. patent grant for its NUC-7738 composition-of-matter.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:15 pm

GRI

GRI Bio has received authorization to conduct a Phase 2a biomarker study for GRI-0621 in Australia, potentially accelerating enrollment in their ongoing study for treating Idiopathic Pulmonary Fibrosis. Interim data is expected in Q4 2024, with topline data in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:15 pm

LFVN

LifeVantage has completed a successful 12-week clinical trial on its new GLP-1 system for weight loss, showing positive results in weight management, reducing food cravings, and improving well-being.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:15 pm

PRAX

Praxis Precision Medicines is set to present Phase 3 clinical data on Ulixacaltamide for essential tremor at the Movement Disorders Society 2024 International Congress in Philadelphia.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:14 pm